Introduction
============

Myelodysplastic syndromes (MDSs) are a heterogeneous clonal disease originating in hematopoietic stem cells and characterized by myeloid dysplasia, impaired differentiation, and peripheral cytopenia ([@b1-ol-0-0-8546]), with estimated incidence rate of 4.3 per 100,000 ([@b2-ol-0-0-8546]). MDS is recognized as a preleukaemic event in which neoplastic clones are established. It frequently evolves to acute leukemia in 20--40% of MDS patients ([@b3-ol-0-0-8546]). MDS originates from multipotent hematopoietic stem cells, which can give rise to both lymphoid and myeloid leukemic cells ([@b4-ol-0-0-8546]). However, progression of MDS to acute lymphocytic leukemia (ALL) is extremely rare, occurring in less than 1% of cases ([@b3-ol-0-0-8546],[@b5-ol-0-0-8546],[@b6-ol-0-0-8546]). To date, there are only 29 reported cases of MDS progressing to ALL. The pathogenesis and prognosis of ALL transformed from MDS is still unclear.

With the advancement of next-generation sequencing, it is possible to identify new somatic mutations that have a potential impact on MDS patients. Mutations in additional sex combs like-1 (ASXL1), an unfavorable prognostic marker, occurs with a frequency of 10--20% in MDS, with 70% being frameshift mutations and 30% being heterozygous point mutations ([@b7-ol-0-0-8546]--[@b9-ol-0-0-8546]). Frameshift or nonsense mutations correlated with shorter survival rates and a higher risk of leukemic transformation ([@b8-ol-0-0-8546],[@b10-ol-0-0-8546],[@b11-ol-0-0-8546]). However, the clinical significance of ASXL1 missense mutations is still questionable. Further research to the role of ASXL1 missense mutations in MDS is required.

In this report, we describe a Chinese male patient harboring an ASXL1 missense mutation. He was diagnosed with pro-B-ALL, transformed from MDS with multiple-lineage dysplasia (MDS-MLD). Furthermore, in order to gain full insight into the clinical features and treatment outcome of ALL transformed from MDS, we analyzed previously reported data from 30 patients for such progression.

Case report
===========

A 33-year-old Chinese man was evaluated for thrombocytopenia in July 2013. On examination, he had splenomegaly. Initial blood counts revealed the following; hemoglobin, 123 g/l; leukocyte count, 7.23×10^9^/l; and platelet count, 23×10^9^/l. Bone marrow examination ([Fig. 1](#f1-ol-0-0-8546){ref-type="fig"}) revealed augmented cellularity and trilineage dysplasia with no increase in myeloblasts dysplasia. Cytogenic testing revealed a normal karyotype 46, XY. Using specific and comprehensive fluorescent *in situ* hybridization (FISH) probe panels showed a lack of demonstrable cytogenetic abnormalities. The patient was diagnosed with MDS-MLD using the World Health Organization classification. Using the revised International Prognostic Scoring System (IPSS-R), he was classified into the low risk category. The patient exhibited persistent thrombocytopenia with progressing anemia. He did not receive any treatment.

After a 47-month history of prolonged bleeding and fatigue, his condition worsened abruptly. Blood counts demonstrated hemoglobin levels at 49 g/l; platelets at 5×10^9^/l; and leukocyte counts at 6.56×10^9^/l. Examination of bone marrow was consistent with a diagnosis of ALL, revealing 63.5% blasts ([Fig. 2A](#f2-ol-0-0-8546){ref-type="fig"}) with numerous micromegakaryocytes by CD41 monoclonal antibody immune enzyme staining ([Fig. 2B](#f2-ol-0-0-8546){ref-type="fig"}). Cytochemical staining demonstrated that the blasts were 95% negative for peroxidase ([Fig. 2C](#f2-ol-0-0-8546){ref-type="fig"}). Cell surface markers analyzed by flow cytometry were positive for CD34, CD19, cCD79a, CD123, and CD38. The blasts also expressed CD33, a myeloid marker. Myeloid cell markers for CD117 and CD13 and T cell markers for cyCD3, CD5, and CD7 were not expressed. The blasts were also negative for CD10, CD15, CD11b, CD64, CD14, CD20, cTDT, cIgM, CD56 and cyMPO. Based on these markers, the patient was diagnosed with Pro-B-ALL. Karyotype analysis of bone marrow leukemic cells revealed normal chromosomes (46, XY). Gene rearrangements were not detected using reverse transcription-PCR.

In addition, known gene mutations associated with MDS were screened using next-generation sequencing techniques. Driver mutant genes include those of RNA splicing (*SF3B1, SRSF2* and *U2AF1*), DNA methylation (*TET2, DNMT3A*, and *IDH1*/*2*), chromatin modification (*ASXL1* and *EZH2*), transcription regulation (*RUNX1*), DNA repair (*TP53*), and signal transduction (*NRAS* and *KRAS*). The patient harbored the point mutation TCC\>TTC in codon 1231 of ASXL1 gene ([Fig. 3](#f3-ol-0-0-8546){ref-type="fig"}), leading to a serine to phenylalanine substitution (S1231F). Other genetic aberrations were not detected in this patient. Subsequently, the patient received chemotherapy beginning the day after bone marrow examination. Treatment regimen included prednisone, vincristine, cyclophosphamide and idarubicin. Unfortunately, the patient passed away due to severe pulmonary infection during the course of chemotherapy. Written informed consent for publication of data was obtained from patient\'s family.

Discussion
==========

We performed an analysis of 30 patients with MDS transforming to ALL (summary in [Table I](#tI-ol-0-0-8546){ref-type="table"}). Clinical characteristics were similar with previous reports in literature ([@b12-ol-0-0-8546],[@b13-ol-0-0-8546]). Patients were predominantly male (76.7%, 23/30) with a median age of 56 years (3--90 years). The median time to transformation was 5.5 months (2--50 months). The common types of MDS with ALL transformation include MDS-excess blasts (MDS-EB) (40%, 12/30), MDS with single-lineage dysplasia (MDS-SLD) (30%, 9/30) and MDS with ring sideroblasts (MDS-RS) (16.7%, 5/30). Majority of the patients transformed to B-cell (66.7%, 16/24) followed by T-cell (33.3%, 8/24) ALL. Using immunophenotyping analysis of our 33 year old male patient, we confirmed the diagnosis of pro-B-ALL due to the bright uniform expression of CD19 and the absence of CD10 surface antigen. The coexpression of CD34 and CD33 myeloid antigens was consistent with the immunophenotypic subtype of pro-B-ALL. Our patient had absence of MLL1/AF4 and BCR/ABL fusion genes, which correlates with a significantly better clinical outcome ([@b14-ol-0-0-8546]). Because of this, our patient was expected to have a good prognosis. However, after a period of prolonged fatigue and bleeding, his condition rapidly deteriorated and he eventually died of severe pulmonary infection due to excess myelosuppression during ALL-directed chemotherapy. His death may be attributed to the nature of MDS transformation.

Although AML evolved from MDS has a poor prognosis, ALL following MDS has not been associated with a poor prognosis as reported in the literature ([@b15-ol-0-0-8546]). However, due to the limited number of cases (9 cases), it is difficult to make any conclusions regarding prognosis. From the 25 cases of MDS transforming to ALL reported in the literature ([Table I](#tI-ol-0-0-8546){ref-type="table"}), 15 patients achieved complete remission (CR) and 1 achieved partial remission (PR). Two cases were refractory and 2 patients failed to achieve a CR after induction treatment. Four patients died during induction therapy and 1 died before therapy. Our results confirm that the complete remission (CR) rate (75%, 15/20) with ALL-directed chemotherapy and the median remission duration of 15 months (range 4.5 to 51 months) are similar with previous reports ([@b15-ol-0-0-8546]). However, ALL following MDS is characterized by a higher rate of early mortality (20%, 5/25).

Genetic aberrations appear to play an important role in the pathogenesis of MDS. ASXL1 gene mutations are one of the characteristic mutations observed for MDS. It encodes a highly conserved protein that belongs to the enhancer of trithorax and polycomb (ETP) genes, a gene family with dual functions in both epigenetic activation and repression of gene transcription ([@b16-ol-0-0-8546]). It contains several nuclear receptor binding motifs and a carboxy-terminal plant homeodomain (PHD) that is predicted to be truncated by frameshift mutations or nonsense mutations ([@b10-ol-0-0-8546],[@b11-ol-0-0-8546]). However, the clinical significance of missense mutations in ASXL1 is unknown. An ASXL1 missense mutation was detected in our patient. This ASXL1 missense mutation did not correspond with other gene mutations identified as adverse prognostic factors. We hypothesize that it may play a substantial role in the progression of our case. The function of ASXL1 is expected to be impaired by this missense mutation.

These novel genetic aberrations in MDS need to be further evaluated regarding their prognostic impact. In our patient, the time to transformation after primary diagnosis was much longer than the median observed. It seems that this missense mutation, unlike frameshift mutations of ASXL1, was not an unfavorable prognostic marker for patients with MDS, which is consistent with previous reports ([@b9-ol-0-0-8546]). Additional studies needs to be conducted to elucidate the influence of ASXL1 missense mutations on the prognosis of patients with MDS.

In summary, we report an ASXL1 missense mutation potentially leading to MDS-MLD transforming to pro-B ALL. This mutation might provide insight into the pathogenesis and prognosis of MDS. ALL following MDS responds well to ALL-directed therapy, but higher rates of early mortality are observed. The prognosis of ALL following MDS needs to be further validated using more uniformly treated patients within a given protocol. Identification of specific gene mutations will hopefully provide for better treatment strategies for this group of patients.
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![MDS-MLD at first admission. BM aspirate smears (Wright-Giemsa stain, ×1,000) revealed hypercellular marrow with dysplastic changes in 3 hematopoietic cell lineages. (A) Granulocytic dysplastic changes, including pseudo Pelger anomaly of the nucleus (a-1), degranulation (a-2), and abnormalities of nuclear segmentation (a-3). (B) Erythroid dysplasia, including binucleation (b-1) and multinuclearity (b-2 and −3). (C) Megakaryocytes exhibited dysplastic changes like small binucleate megakaryocyte (c-1), micromegakaryocytes (c-2) and megakaryocyte with isolated multi-nuclei (c-3).](ol-15-06-9745-g00){#f1-ol-0-0-8546}

![ALL at second admission. BM aspiration smear (Wright-Giemsa stain, ×1,000) exhibits a markedly increased number of lymphoblasts (A) and micromegakaryocytes by CD41 monoclonal antibody immune enzyme staining (B). The lymphoblasts were 5% positive for POX staining (C).](ol-15-06-9745-g01){#f2-ol-0-0-8546}

![Point mutation TCC\>TTC in codon 1231 of ASXL1 gene.](ol-15-06-9745-g02){#f3-ol-0-0-8546}

###### 

Previously reported cases of lymphoid transformation of myelodysplastic syndrome.

  No.   Age (y)   Sex   Time to transformation (months)   Initial diagnosis of MDS   Phenotype of blast at transformation   Chromosomal abnormalities                                     Outcome                  Survival     (Refs.)
  ----- --------- ----- --------------------------------- -------------------------- -------------------------------------- ------------------------------------------------------------- ------------------------ ------------ ----------------------
    1   68        M     31                                RS                         B-cell                                 +8                                                            Early death              --           ([@b6-ol-0-0-8546])
    2   68        F     5                                 EB                         B-cell                                 45XX, −3, del(5)(q13q31)\[4\]/46,XX\[16\]                     Death during induction   --           ([@b17-ol-0-0-8546])
    3   43        M     11                                Eosinophilic MDS           B-cell                                 45,XY, del(5q)(q22q23), −7, add(12)(p13)\[5\]                 Death during induction   --           ([@b18-ol-0-0-8546])
    4   58        M     20                                RA                         L                                      not available                                                 Death during induction   --           ([@b19-ol-0-0-8546])
    5   33        M     47                                MLD                        B-ALL                                  Normal                                                        Death during induction   --           Current case
    6   67        M     18                                EB                         T-cell                                 45XY, −7                                                      Fail                     --           ([@b15-ol-0-0-8546])
    7   78        M     5                                 RS                         T-cell                                 --                                                            Fail                     --           ([@b15-ol-0-0-8546])
    8   54        M     30                                SLD                        B-cell                                 46,XY,t(9;22)(q34;q11), 20q-                                  Refractory               --           ([@b20-ol-0-0-8546])
    9   28        F     11                                SLD                        B-cell                                 Normal                                                        Refractory               --           ([@b21-ol-0-0-8546])
  10    65        M     18                                SLD                        B-cell                                 +13, partially tetraploid                                     PR                                    ([@b22-ol-0-0-8546])
  11    53        F     2                                 MDS with myelofibrosis     B cell                                 Normal                                                        CR                       Alive        ([@b12-ol-0-0-8546])
  12      3       M                                       EB                         Pre-B-cell                                                                                           CR                       --           ([@b23-ol-0-0-8546])
  13      4       M     NA                                EB                         ALL                                    5q-                                                           CR                       19 months    ([@b24-ol-0-0-8546])
  14      5       M     4                                 EB                         B cell                                 not available                                                 CR                       Alive        ([@b13-ol-0-0-8546])
  15    46        M     2                                 EB                         Pre B cell                             --                                                            CR                       Alive        ([@b25-ol-0-0-8546])
  16    50        M     4                                 SLD                        B-cell                                 Complex                                                       CR                       --           ([@b26-ol-0-0-8546])
  17    67        M     24                                RS                         --                                     Aneuploidy                                                    CR                       12 months    ([@b27-ol-0-0-8546])
  18    53        M     50                                RS                         Null cell                              not available                                                 CR                       11 months    ([@b28-ol-0-0-8546])
  19    20        M     5                                 EB                         T cell                                 not available                                                 CR                       24 months    ([@b29-ol-0-0-8546])
  20    50        F     3                                 EB                         cALL                                   Normal                                                        CR                       Alive        ([@b30-ol-0-0-8546])
  21    65        M     4                                 EB                         T-cell                                 46XY\[7\]/47XY, +8\[7\]/48XY, +8,+13\[1\]/48XY, +8,+20\[1\]   CR                       51 months    ([@b15-ol-0-0-8546])
  22    72        F     5                                 RS                         T-cell                                 Normal                                                        CR                       4.5 months   ([@b15-ol-0-0-8546])
  23    69        M     6                                 SLD                        T-cell                                 46XY\[9\]/47XY, +8\[1\]                                       CR                       15 months    ([@b15-ol-0-0-8546])
  24    72        M     5                                 EB                         T-cell                                 Normal                                                        CR                       12 months    ([@b15-ol-0-0-8546])
  25    62        F     2                                 SLD                        B-cell                                 --                                                            CR                       25 months    ([@b31-ol-0-0-8546])
  26      9       M     21                                SLD                        B-cell                                 not available                                                 not available            --           ([@b32-ol-0-0-8546])
  27    90        M     5                                 EB                         cALL                                   not done                                                      not available            --           ([@b33-ol-0-0-8546])
  28    75        M     18                                EB                         T-cell                                 Normal                                                        not available            --           ([@b34-ol-0-0-8546])
  29    70        M     22                                SLD                        B-cell                                 --                                                            not available            --           ([@b35-ol-0-0-8546])
  30      8       F     3                                 RCC                        B cell                                 Normal                                                        not available            --           ([@b36-ol-0-0-8546])
